Tréhoux Solange, Lahdaoui Fatima, Delpu Yannick, Renaud Florence, Leteurtre Emmanuelle, Torrisani Jérôme, Jonckheere Nicolas, Van Seuningen Isabelle
Inserm, UMR-S1172, Jean-Pierre Aubert Research Center, Team "Mucins, Epithelial Differentiation and Carcinogenesis", Rue Polonovski, 59045 Lille cedex, France; Université de Lille 2, 42 rue Paul Duez, 59000 Lille, France; Centre Hospitalier Régional et Universitaire de Lille, 59037 Lille cedex, France.
Inserm, UMR1037, Cancer Research Center of Toulouse, 1 avenue Jean Poulhes, 31432 Toulouse cedex 4, France.
Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2392-403. doi: 10.1016/j.bbamcr.2015.05.033. Epub 2015 May 31.
MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To control cancer progression, miRNAs became very recently, major targets and tools to inhibit oncogene expression. Inhibiting MUC1 using miRNAs appears thus as an attractive strategy to reduce cancer progression. However, potent miRNAs and associated mechanisms regulating MUC1 expression remain to be identified. To this aim, we undertook to study MUC1 regulation by miRNAs in pancreatic cancer cells and identify those with tumor suppressive activity. MiRNAs potentially targeting the 3'-UTR, the coding region, or the 5'-UTR of MUC1 were selected using an in silico approach. Our in vitro and in vivo experiments indicate that miR-29a and miR-330-5p are strong inhibitors of MUC1 expression in pancreatic cancer cells through direct binding to MUC1 3'-UTR. MUC1 regulation by the other selected miRNAs (miR-183, miR-200a, miR-876-3p and miR-939) was found to be indirect. MiR-29a and miR-330-5p are also deregulated in human pancreatic cancer cell lines and tissues and in pancreatic tissues of Kras(G12D) mice. In vitro, miR-29a and miR-330-5p inhibit cell proliferation, cell migration, cell invasion and sensitize pancreatic cancer cells to gemcitabine. In vivo intra-tumoral injection of these two miRNAs in xenografted pancreatic tumors led to reduced tumor growth. Altogether, we have identified miR-29a and miR-330-5p as two new tumor suppressive miRNAs that inhibit the expression of MUC1 oncogenic mucin in pancreatic cancer cells.
粘蛋白1(MUC1)是一种致癌粘蛋白,在包括胰腺导管腺癌在内的多种上皮癌中过表达,被认为是癌症治疗的一个有力靶点。为了控制癌症进展,微小RNA(miRNA)最近成为抑制癌基因表达的主要靶点和工具。因此,利用miRNA抑制MUC1似乎是一种减少癌症进展的有吸引力的策略。然而,调节MUC1表达的有效miRNA及其相关机制仍有待确定。为此,我们着手研究miRNA对胰腺癌细胞中MUC1的调控,并鉴定具有肿瘤抑制活性的miRNA。使用计算机方法选择可能靶向MUC1的3'-非翻译区(UTR)、编码区或5'-UTR的miRNA。我们的体外和体内实验表明,miR-29a和miR-330-5p通过直接结合MUC1的3'-UTR,是胰腺癌细胞中MUC1表达的强效抑制剂。发现其他所选miRNA(miR-183、miR-200a、miR-876-3p和miR-939)对MUC1的调控是间接的。miR-29a和miR-330-5p在人胰腺癌细胞系和组织以及Kras(G12D)小鼠的胰腺组织中也失调。在体外,miR-29a和miR-330-5p抑制细胞增殖、细胞迁移、细胞侵袭,并使胰腺癌细胞对吉西他滨敏感。在体内,将这两种miRNA瘤内注射到异种移植的胰腺肿瘤中可导致肿瘤生长减缓。总之,我们已确定miR-29a和miR-330-5p是两种新的肿瘤抑制性miRNA,它们可抑制胰腺癌细胞中致癌粘蛋白MUC1的表达。